NGM Biopharmaceuticals, Inc.
NGM Biopharmaceuticals, Inc. (NGM) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · NGM · as of Mar 31, 2024
Ownership Breakdown
74
Institutional Holders
▼ 9 vs Q4
$55.14M
Total Inst. Value
▲ $19.82M vs Q4
83.46M
Shares Outstanding
freeFloat 34.61%
34.63M
13F Shares Held
▼ 6.49M vs Q4
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
NGM largest shareholders · institutional ownership
Q1 2024 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
COLUMN GROUP LLC pharmaceutical preparations | 18.14M | 21.90% | 21.90% | $28.84B | May 15, 2024 | — held |
BLACKROCK INC. pharmaceutical preparations | 3.00M | 3.63% | 3.63% | $4.78B | May 10, 2024 | ▼ 174.0K |
VANGUARD GROUP INC pharmaceutical preparations | 2.32M | 2.81% | 2.81% | $3.70B | May 10, 2024 | ▼ 446.2K |
STEPSTONE GROUP LP pharmaceutical preparations | 1.57M | 1.90% | 1.90% | $2.50B | May 13, 2024 | — held |
EUCLIDEAN CAPITAL LLC pharmaceutical preparations | 992.2K | 1.20% | 1.20% | $1.58B | May 15, 2024 | — held |
GEODE CAPITAL MANAGEMENT, LLC pharmaceutical preparations | 983.8K | 1.19% | 1.19% | $1.56B | May 13, 2024 | ▲ 62.2K |
TRIUM CAPITAL LLP pharmaceutical preparations | 978.0K | 1.18% | 1.18% | $1.55B | May 14, 2024 | NEW |
STATE STREET CORP pharmaceutical preparations | 823.1K | 99.41% | 99.41% | $1.31B | May 15, 2024 | ▲ 712 |
ADAR1 CAPITAL MANAGEMENT, LLC pharmaceutical preparations | 816.6K | 98.62% | 98.62% | $1.30B | May 15, 2024 | NEW |
RENAISSANCE TECHNOLOGIES LLC pharmaceutical preparations | 611.3K | 73.83% | 73.83% | $972.00M | May 13, 2024 | ▼ 145.6K |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q1 2024 vs prior quarter
Q1 2024
13
Increased
+708.2K shares8
New Positions
first time holders20
Decreased
−3.55M shares0
Sold Out
fully exitedNet shares change (top 50)
2.84M
+708.2K / −3.55M
Net new holders
+1
8 new / 0 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
NGM insider trading · insider activity
Source: SEC Form 4
0
Buy transactions
4
Sell transactions
0.00
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
TCG Opportunity III GP, LLC 10 percent owner | Apr 5, 2024 | J-Other | 1,000 | — | — | 1.0K | Form 4 ↗ |
TCG Opportunity III GP, LLC 10 percent owner | Apr 5, 2024 | D-Return | 44,000 | — | — | 0 | Form 4 ↗ |
COLUMN GROUP GP, LP 10 percent owner | Apr 5, 2024 | J-Other | 1,000 | — | — | 1.0K | Form 4 ↗ |
COLUMN GROUP GP, LP 10 percent owner | Apr 5, 2024 | D-Return | 44,000 | — | — | 0 | Form 4 ↗ |
COLUMN GROUP L P
| Apr 5, 2024 | J-Other | 1,000 | — | — | 1.0K | Form 4 ↗ |
COLUMN GROUP L P
| Apr 5, 2024 | D-Return | 44,000 | — | — | 0 | Form 4 ↗ |
GOEDDEL DAVID V
| Apr 5, 2024 | J-Other | 1,000 | — | — | 1.0K | Form 4 ↗ |
GOEDDEL DAVID V
| Apr 5, 2024 | D-Return | 100,000 | — | — | 0 | Form 4 ↗ |
GOEDDEL DAVID V
| Apr 5, 2024 | D-Return | 24,000 | $13.35 | $320.4K | 0 | Form 4 ↗ |
GOEDDEL DAVID V
| Apr 5, 2024 | D-Return | 19,619 | $17.24 | $338.2K | 0 | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
NGM Biopharmaceuticals, Inc. (NGM) is primarily owned by institutional investors, who hold approximately 41.5% of total shares outstanding. Company insiders own approximately 65.39%, while retail and public investors account for the remaining 0.00%.
The largest institutional shareholder of NGM Biopharmaceuticals, Inc. is COLUMN GROUP LLC, holding approximately 18.14 million shares — equal to 21.90% of outstanding shares — as of March 31, 2024.
A total of 74 institutional investors currently hold NGM stock, with a combined institutional value of approximately $55,144,419 as of the most recent 13F filing period.
Frequently asked questions
NGM ownershipNGM Biopharmaceuticals, Inc. (NGM) is primarily owned by institutional investors, who hold approximately 41.5% of shares. The largest shareholder is COLUMN GROUP LLC with a 21.90% stake. Company insiders hold 65.39%. Data sourced from SEC Form 13F as of March 31, 2024.